Does MapLight Therapeutics, Inc. have the clinical design to compete in crowded neuropsychiatric markets?

MapLight Therapeutics nears key Phase 2 data in schizophrenia and autism. Discover how its trial design could shape CNS market competition.

MapLight Therapeutics nears key Phase 2 data in schizophrenia and autism. Discover how its trial design could shape CNS market competition.